almonertinib
Small moleculeexperimental
Clinical trial activity
46 trials · 50 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
40
Phase 3
12
Phase 4
0
Earliest trial started Jun 30, 2020 (NCT04354961)
Timeline
Indications
Studied for
- Brain Neoplasms · Phase 3
- Carcinoma · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 3
- Drug Therapy · Phase 2
- Epidermal Growth Factor · Phase 2
- Genes, erbB-2 · Phase 2
- Lung Neoplasms · Phase 2/Phase 3
- Lymphoma · Phase 1
- Mutation · Phase 3
- Neoplasms · Phase 1/Phase 2
- Pharmacological and Toxicological Phenomena · Phase 2
- Radiotherapy · Phase 3
- Safety · Phase 2
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07229729 | Phase 2 | Nov 30, 2025 | Hengrui Therapeutics, Inc. |
| NCT06951464 | Phase 2 | Jun 25, 2025 | Sichuan University |
| NCT06947811 | Phase 1/Phase 2 (Phase 2) | Jun 9, 2025 | Sun Yat-Sen University |
| NCT06585059 | Phase 1 | Sep 30, 2024 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT06474455 | Phase 1/Phase 2 (Phase 2) | Jun 30, 2024 | Hengrui Therapeutics, Inc. |
| NCT06463171 | Phase 2 | Jun 30, 2024 | Fudan University, Huazhong University of Science and Technology, Xiamen University |
| NCT06452433 | Phase 2 | Jun 1, 2024 | Chinese Academy of Medical Sciences |
| NCT06300424 | Phase 2 | Apr 30, 2024 | Shantou University |
| NCT06185400 | Phase 2 | Feb 1, 2024 | Chinese Academy of Medical Sciences |
| NCT06110663 | Phase 3 | Dec 30, 2023 | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| NCT06092268 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2023 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT05994339 | Phase 2/Phase 3 (Phase 3) | Sep 1, 2023 | Laibin people's Hospital |
| NCT06043973 | Phase 3 | Sep 1, 2023 | Shandong Province Qianfoshan Hospital |
| NCT05768490 | Phase 3 | Mar 15, 2023 | Sun Yat-Sen University |
| NCT05800223 | Phase 3 | Jan 1, 2023 | Fudan University |
| NCT05810350 | Phase 2 | Jan 1, 2023 | Chongqing Medical University |
| NCT05534113 | Phase 2 | Dec 1, 2022 | Nanjing Medical University |
| NCT05662813 | Phase 2 | Nov 9, 2022 | Sichuan University |
| NCT05503888 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2022 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT04755738 | Phase 2 | Jan 1, 2022 | Shandong Province Qianfoshan Hospital, Shandong Provincial Hospital |
Showing 20 of 46 trials
Page 1 / 3
Organizations
Research & Development (50)
50 organizations
Page 1 / 3